Disc Medicine Inc. Net Assets
Disc Medicine Inc. net assets. Based on the latest financial reports, Disc Medicine Inc. (IRON) has net assets worth $644.16 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($735.07 Million) and total liabilities ($90.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IRON shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $644.16 Million |
| % of Total Assets | 87.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 27.4 |
Net Assets of Disc Medicine Inc. (2020–2025)
Net assets of Disc Medicine Inc. from 2020 to 2025. This chart illustrates how Disc Medicine Inc.'s net assets have evolved over time, based on quarterly financial data. See Disc Medicine Inc. (IRON) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Disc Medicine Inc. (2020–2025)
The table below shows the annual net assets of Disc Medicine Inc. from 2020 to 2025. For live market cap and overall valuation, see IRON stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $739.83 Million | +66.78% |
| 2024-12-31 | $443.59 Million | +28.53% |
| 2023-12-31 | $345.12 Million | +95.43% |
| 2022-12-31 | $176.60 Million | +375.07% |
| 2021-12-31 | $-64.20 Million | -193.69% |
| 2020-12-31 | $-21.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Disc Medicine Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39736500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Disc Medicine Inc. Net Assets Breakdown (December 2025)
Disc Medicine Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $965.00K | 0.13% |
| Other Components | $1.25 Billion | 168.83% |
| Total Equity | $739.83 Million | 100.00% |
Disc Medicine Inc. Competitors by Market Cap
The table below lists competitors of Disc Medicine Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dalmia Bharat Limited
NSE:DALBHARAT
|
$2.69 Billion |
|
Joincare Pharmaceutical Group Industry Co Ltd
SHG:600380
|
$2.69 Billion |
|
Gold Road Resources Ltd
AU:GOR
|
$2.69 Billion |
|
China International Marine Containers (Group) Co. Ltd
F:OCM
|
$2.69 Billion |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
$2.69 Billion |
|
OLAM GROUP LTD
F:K25
|
$2.69 Billion |
|
FRASERS PROPERTY
F:1IQ
|
$2.69 Billion |
|
Bandhan Bank Limited
NSE:BANDHANBNK
|
$2.69 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Disc Medicine Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 443,587,000 to 739,826,000, a change of 296,239,000 (66.8%).
- Net loss of 212,184,000 reduced equity.
- New share issuances of 450,112,000 increased equity.
- Other comprehensive income increased equity by 676,000.
- Other factors increased equity by 57,635,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-212.18 Million | -28.68% |
| Share Issuances | $450.11 Million | +60.84% |
| Other Comprehensive Income | $676.00K | +0.09% |
| Other Changes | $57.63 Million | +7.79% |
| Total Change | $- | 66.78% |
Book Value vs Market Value Analysis
This analysis compares Disc Medicine Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-14.46 | $80.84 | x |
| 2021-12-31 | $-80.11 | $80.84 | x |
| 2022-12-31 | $169.89 | $80.84 | x |
| 2023-12-31 | $15.47 | $80.84 | x |
| 2024-12-31 | $16.07 | $80.84 | x |
| 2025-12-31 | $20.96 | $80.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Disc Medicine Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-28.68%) is below the historical average (-16.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-38.65 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.55 Million |
| 2022 | -26.10% | 0.00% | 0.00x | 1.13x | $-63.75 Million |
| 2023 | -22.15% | 0.00% | 0.00x | 1.07x | $-110.94 Million |
| 2024 | -24.65% | 0.00% | 0.00x | 1.12x | $-153.72 Million |
| 2025 | -28.68% | 0.00% | 0.00x | 1.09x | $-286.17 Million |
Industry Comparison
This section compares Disc Medicine Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Disc Medicine Inc. (IRON) | $644.16 Million | 0.00% | 0.14x | $2.69 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more